Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

Peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines displaying tissue-specific autoantigenic epitopes can blunt specific autoimmune conditions by re-programming cognate antigen-experienced CD4+ T-cells into disease-suppressing T-regulatory type 1 (TR1) cells. Here, we show...

Descripción completa

Detalles Bibliográficos
Autores principales: Umeshappa, Channakeshava Sokke, Singha, Santiswarup, Blanco, Jesus, Shao, Kun, Nanjundappa, Roopa Hebbandi, Yamanouchi, Jun, Parés, Albert, Serra, Pau, Yang, Yang, Santamaria, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517389/
https://www.ncbi.nlm.nih.gov/pubmed/31089130
http://dx.doi.org/10.1038/s41467-019-09893-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517389/
https://www.ncbi.nlm.nih.gov/pubmed/31089130
http://dx.doi.org/10.1038/s41467-019-09893-5

Ejemplares similares